<DOC>
	<DOCNO>NCT00485615</DOCNO>
	<brief_summary>The primary objective evaluate efficacy enteric-coated , eicosapentaenoic acid-concentrated fish oil treatment social phobia . A secondary objective determine treatment outcome relate plasma phospholipid essential fatty acid status , niacin skin flush measure lipid/protein peroxidation .</brief_summary>
	<brief_title>An Open Label Trial Omega 3 ( o3mega+Joy ) Treatment Social Phobia</brief_title>
	<detailed_description>Subjects meet criterion Social Anxiety Disorder , receive enteric-coated , eicosapentaenoic acid-concentrated fish oil ( O3mega+Joy ) 12 week treatment social phobia . A secondary objective determine treatment outcome relate change plasma phospholipid essential fatty acid status , niacin skin flush measure lipid/protein change .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<criteria>Eligible trial patient meet follow criterion : 1 . The patient provide sign informed consent . 2 . Outpatients age 1865 ( extreme include ) . 3 . Patients primary diagnosis Social Phobia accord DSM IV ( 300.23 ) criterion ( diagnosis make use Mini International Neuropsychiatric Interview ( MINI ) ) . 4 . On basis physical examination , medical history basic laboratory screening , patient , investigator opinion , suitable condition . 5 . Willing able attend study appointment correct time window . Patients meet one follow criterion select inclusion : 1 . Any axis I diagnosis primary disorder previous six month . 2 . Continuation commencement formal psychotherapy . 3 . Alcohol drug abuse define DSM IV within last six month . 4 . Mania hypomania define DSM IV . 5 . Current use commencement antidepressant anxiolytic medication . 6 . Patients antidepressant anxiolytic prior study , discontinue two week prior entry study . Those fluoxetine , least 5 week 7 . Patients herbal alternative treatment judge potentially anxiolytic psychobiological activity , terminate usage agent two week prior enter study.. 8 . Any psychotic disorder . 9 . Eating disorder define DSM IV . 10 . Mental retardation cognitive disorder . 11 . Clinical interpretation apparent suicide risk . 12 . Previous treatment effort use 4000mg fish oil daily . 13 . Current use commencement essential fatty acid supplementation . 14 . Significant alteration Standard North American Diet ie special diet either restrictive inclusive typical carbohydrate , protein fat intake . 15 . Known sensitivity fish oil fish product . 16 . Any disorder clot current use warfarin . 17 . Laboratory value screen medical history may consider clinical interpretation significant . 18 . Diseases could , clinical interpretation , interfere assessment safety , tolerability efficacy . 19 . Serious illness : Liver renal insufficiency , cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurological , infectious , neoplastic metabolic disturbance . 20 . The patient , opinion investigator , unlikely able comply clinical trial protocol , unsuitable reason . 21 . Pregnant breastfeeding female 22 . Females childbearing year use contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>eicosapentaenoic acid</keyword>
	<keyword>fish oil</keyword>
	<keyword>Omega 3</keyword>
	<keyword>Social Anxiety Disorder</keyword>
</DOC>